Literature DB >> 27329032

β-Lactams and β-Lactamase Inhibitors: An Overview.

Karen Bush1, Patricia A Bradford2.   

Abstract

β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of β-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options. This work provides a comprehensive overview of β-lactam antibiotics that are currently in use, as well as a look ahead to several new compounds that are in the development pipeline.
Copyright © 2016 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27329032      PMCID: PMC4968164          DOI: 10.1101/cshperspect.a025247

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  137 in total

Review 1.  Carbapenems in clinical practice: a guide to their use in serious infection.

Authors:  J S Bradley; J Garau; H Lode; K V Rolston; S E Wilson; J P Quinn
Journal:  Int J Antimicrob Agents       Date:  1999-02       Impact factor: 5.283

Review 2.  Management of Staphylococcus aureus infections.

Authors:  David M Bamberger; Sarah E Boyd
Journal:  Am Fam Physician       Date:  2005-12-15       Impact factor: 3.292

Review 3.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

Review 4.  Emerging issues in gram-negative bacterial resistance: an update for the practicing clinician.

Authors:  Shawn Vasoo; Jason N Barreto; Pritish K Tosh
Journal:  Mayo Clin Proc       Date:  2015-03       Impact factor: 7.616

5.  Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study.

Authors:  Pattarachai Kiratisin; Anan Chongthaleong; Thean Yen Tan; Evelina Lagamayo; Sally Roberts; Jemelyn Garcia; Todd Davies
Journal:  Int J Antimicrob Agents       Date:  2012-03-03       Impact factor: 5.283

6.  Penetration of meropenem into the cerebrospinal fluid of patients with inflamed meninges.

Authors:  R Dagan; L Velghe; J L Rodda; K P Klugman
Journal:  J Antimicrob Chemother       Date:  1994-07       Impact factor: 5.790

7.  FDA approves new antibiotic for surgical infections, meningitis.

Authors: 
Journal:  Hospitals       Date:  1982-07-16

8.  Diversity of extended-spectrum and plasmid-mediated AmpC β-lactamases in Enterobacteriaceae isolates from Portuguese health care facilities.

Authors:  Daniela Jones-Dias; Vera Manageiro; Eugénia Ferreira; Deolinda Louro; Manuela Caniça
Journal:  J Microbiol       Date:  2014-05-29       Impact factor: 3.422

9.  Reversible inhibitors of penicillinases.

Authors:  P A Kiener; S G Waley
Journal:  Biochem J       Date:  1978-01-01       Impact factor: 3.857

10.  Enhanced bleeding with cefoxitin or moxalactam. Statistical analysis within a defined population of 1493 patients.

Authors:  R B Brown; J Klar; S Lemeshow; D Teres; H Pastides; M Sands
Journal:  Arch Intern Med       Date:  1986-11
View more
  164 in total

1.  The Natural Product Elegaphenone Potentiates Antibiotic Effects against Pseudomonas aeruginosa.

Authors:  Weining Zhao; Ashley R Cross; Caillan Crowe-McAuliffe; Angela Weigert-Munoz; Erika E Csatary; Amy E Solinski; Joanna Krysiak; Joanna B Goldberg; Daniel N Wilson; Eva Medina; William M Wuest; Stephan A Sieber
Journal:  Angew Chem Int Ed Engl       Date:  2019-05-16       Impact factor: 15.336

Review 2.  Bacterial proteases, untapped antimicrobial drug targets.

Authors:  Elizabeth Culp; Gerard D Wright
Journal:  J Antibiot (Tokyo)       Date:  2016-11-30       Impact factor: 2.649

3.  ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.

Authors:  Thomas F Durand-Réville; Satenig Guler; Janelle Comita-Prevoir; Brendan Chen; Neil Bifulco; Hoan Huynh; Sushmita Lahiri; Adam B Shapiro; Sarah M McLeod; Nicole M Carter; Samir H Moussa; Camilo Velez-Vega; Nelson B Olivier; Robert McLaughlin; Ning Gao; Jason Thresher; Tiffany Palmer; Beth Andrews; Robert A Giacobbe; Joseph V Newman; David E Ehmann; Boudewijn de Jonge; John O'Donnell; John P Mueller; Rubén A Tommasi; Alita A Miller
Journal:  Nat Microbiol       Date:  2017-06-30       Impact factor: 17.745

Review 4.  Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections.

Authors:  Yu-Xuan Ma; Chen-Yu Wang; Yuan-Yuan Li; Jing Li; Qian-Qian Wan; Ji-Hua Chen; Franklin R Tay; Li-Na Niu
Journal:  Adv Sci (Weinh)       Date:  2019-12-05       Impact factor: 16.806

5.  Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.

Authors:  Sarah M McLeod; Adam B Shapiro; Samir H Moussa; Michele Johnstone; Robert E McLaughlin; Boudewijn L M de Jonge; Alita A Miller
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

6.  In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem.

Authors:  Nicole Cotroneo; Aileen Rubio; Ian A Critchley; Chris Pillar; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

7.  DeepBL: a deep learning-based approach for in silico discovery of beta-lactamases.

Authors:  Yanan Wang; Fuyi Li; Manasa Bharathwaj; Natalia C Rosas; André Leier; Tatsuya Akutsu; Geoffrey I Webb; Tatiana T Marquez-Lago; Jian Li; Trevor Lithgow; Jiangning Song
Journal:  Brief Bioinform       Date:  2021-07-20       Impact factor: 11.622

Review 8.  Resistance to Novel β-Lactam-β-Lactamase Inhibitor Combinations: The "Price of Progress".

Authors:  Krisztina M Papp-Wallace; Andrew R Mack; Magdalena A Taracila; Robert A Bonomo
Journal:  Infect Dis Clin North Am       Date:  2020-09-30       Impact factor: 5.982

9.  In Vitro Activity of the Ultra-Broad-Spectrum Beta-Lactamase Inhibitor QPX7728 in Combination with Meropenem against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Kirk Nelson; Debora Rubio-Aparicio; Ruslan Tsivkovski; Dongxu Sun; Maxim Totrov; Michael Dudley; Olga Lomovskaya
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

10.  In Vivo Activity of QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor, in Combination with Beta-Lactams against Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.